These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 24512308)

  • 81. Histone deacetylase inhibitors: a patent review (2009 - 2011).
    Carafa V; Miceli M; Altucci L; Nebbioso A
    Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 83. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
    Fujii K; Suzuki N; Jimura N; Idogawa M; Kondo T; Iwatsuki K; Kanekura T
    J Dermatol Sci; 2018 Apr; 90(1):82-89. PubMed ID: 29395577
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach.
    Ma X; Ma Q; Liu J; Tian Y; Wang B; Taylor KM; Wu P; Wang D; Xu G; Meng L; Wang S; Ma D; Zhou J
    Mol Cancer Ther; 2009 Nov; 8(11):3108-16. PubMed ID: 19887557
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Drug Combinations with HDAC Inhibitors in Antitumor Therapy.
    Arrighetti N; Corno C; Gatti L
    Crit Rev Oncog; 2015; 20(1-2):83-117. PubMed ID: 25746106
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
    Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
    Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
    Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
    DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers.
    Wang X; Jackson LN; Johnson SM; Wang Q; Evers BM
    Mol Cancer Ther; 2010 Aug; 9(8):2389-98. PubMed ID: 20663927
    [TBL] [Abstract][Full Text] [Related]  

  • 89. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
    Lopez G; Torres K; Liu J; Hernandez B; Young E; Belousov R; Bolshakov S; Lazar AJ; Slopis JM; McCutcheon IE; McConkey D; Lev D
    Cancer Res; 2011 Jan; 71(1):185-96. PubMed ID: 21084276
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
    Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
    Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
    Díaz-Núñez M; Díez-Torre A; De Wever O; Andrade R; Arluzea J; Silió M; Aréchaga J
    BMC Cancer; 2016 Aug; 16(1):667. PubMed ID: 27549189
    [TBL] [Abstract][Full Text] [Related]  

  • 93. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
    Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
    Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
    Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
    Sooraj D; Xu D; Cain JE; Gold DP; Williams BR
    Mol Cancer Ther; 2016 Jul; 15(7):1726-39. PubMed ID: 27196751
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Sodium Butyrate Enhances the Cytotoxic Effect of Etoposide in HDACi-Sensitive and HDACi-Resistant Transformed Cells.
    Gnedina OO; Morshneva AV; Igotti MV
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958894
    [TBL] [Abstract][Full Text] [Related]  

  • 97. New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
    Gueugnon F; Cartron PF; Charrier C; Bertrand P; Fonteneau JF; Gregoire M; Blanquart C
    Oncotarget; 2014 Jun; 5(12):4504-15. PubMed ID: 24980825
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
    Suraweera A; O'Byrne KJ; Richard DJ
    Front Oncol; 2018; 8():92. PubMed ID: 29651407
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells.
    Cho E; Rowan-Carroll A; Williams A; Corton JC; Li HH; Fornace AJ; Hobbs CA; Yauk CL
    Arch Toxicol; 2021 May; 95(5):1631-1645. PubMed ID: 33770205
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
    Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
    Exp Cell Res; 2024 Jun; 439(1):114055. PubMed ID: 38704080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.